Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity - Wikidata - awgldk - TriplyDB

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

http://www.wikidata.org/entity/Q24652600

about

Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling Raf family kinases: old dogs have learned new tricks Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Analysis of the genome to personalize therapy for melanoma PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells BRAF mutations in hairy-cell leukemia Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF DHODH modulates transcriptional elongation in the neural crest and melanoma Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Therapeutic Implications of Targeting AKT Signaling in Melanoma Improved survival with vemurafenib in melanoma with BRAF V600E mutation FOXD3 regulates migration properties and Rnd3 expression in melanoma cells Process of Fragment-Based Lead Discovery-A Perspective from NMR Tailoring the Treatment of Melanoma: Implications for Personalized Medicine Mitochondrial Dysfunction and Disturbed Coherence: Gate to Cancer.What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma The GIST of targeted therapy for malignant melanoma Chloroquine and hydroxychloroquine for cancer therapy Emerging targeted therapies for melanoma treatment (review)Ten things you should know about protein kinases: IUPHAR Review 14 Structure based approaches for targeting non-coding RNAs with small molecules Targeting tyrosine kinases in cancer: the converging roles of cytopathology and molecular pathology in the era of genomic medicine Personalised cancer medicine Current and future trials of targeted therapies in cutaneous melanoma Melanoma: from mutations to medicine Mutation of the BRAF genes in non-small cell lung cancer Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent The Crystal Structure of BRAF in Complex with an Organoruthenium Inhibitor Reveals a Mechanism for Inhibition of an Active Form of BRAF Kinase Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor

P2860

Q21004109-C5847B30-3070-4A0B-86C6-84E5CF73CF56 Q21133611-4B085245-22D5-4866-A879-0B5DB55C6BFB Q21629049-F7BB876C-921B-403D-8F43-2A4057AA324C Q24298749-DD1E365A-F7CC-459D-AA1F-3AB2219399BE Q24300674-E5A31A64-1CB6-450D-AE33-11EAB5424C5C Q24303940-C863F981-D824-4ED1-810B-898842333952 Q24314807-A31400AE-639D-4AED-B34E-0E56B3049656 Q24316181-869DFECB-0903-4996-B181-FFCED0D15D4E Q24594790-8DAF264F-0829-42AA-8E8C-76C0F9188F83 Q24597152-1ED07869-A260-4703-8625-61335D6CA06B Q24601008-90707037-B2BB-4E1E-9D7A-FA5B88B255DC Q24606438-518187B5-D2EE-4394-B133-A323F8300801 Q24609980-286F1C0B-8F2A-4155-8B4A-3899AF1BDDCD Q24615826-25CA118E-C9C2-458D-A91E-60F65C7B3A19 Q24629043-0085DB78-0887-457C-A5F2-03CF80F7C589 Q24629474-F87CC863-83AC-4813-9206-82A88B9A91EF Q24631438-0E9A307D-FCDB-4011-84D7-808693140347 Q24631953-0F83A01B-57E5-4243-9823-DC51DB3BC739 Q24633339-4508A8BF-8C73-48EE-A9BB-4BEDA4176325 Q26738768-EC9C23AF-7488-4BCF-8433-D9D10D4DC9CE Q26775806-8A36BDCF-1509-44AE-9A35-18D8036B3EED Q26782068-AE3DE034-615C-4CD7-92E3-7B4E73476BEA Q26782585-82F71F19-B47C-42A3-8DA6-7C4911CFEC72 Q26783032-8A833803-4C52-4170-967C-53F60DF1E69B Q26824310-802EF325-8520-47D6-ACFB-558896418F1F Q26827092-81CEBC34-A708-4D71-A48D-DCDE0B61FCFB Q26827797-64B2DE31-75C0-40F4-A2DD-FD0D9CC82CB2 Q26829997-C3A61E32-672B-400C-B7BC-E77A8B30959C Q26849417-DD7B56DE-34F4-481C-AC5C-688990C6BEB9 Q26858823-0A4A3529-2BEF-4D4F-9C3E-518896487D5B Q26865436-8E0F6BDE-08A8-494E-AA49-2FA80CF30312 Q26991908-FE2839E7-C648-4C17-9069-2BB2318B873F Q27022355-03A2EF47-1A9B-4531-ABA6-8260A42B0AF3 Q27024061-91A9B0ED-4EC5-4A48-9DC6-3234E0A3F48C Q27025345-1F73A42E-9794-4542-88E2-0FD584450EB4 Q27026323-30A8C3C1-369C-4F90-B83C-76CFC5FE2DAB Q27653305-140A7E93-FB00-4778-88C5-34968043F276 Q27654846-1E84AA70-1392-4289-8BAE-8B5714DFCD01 Q27658766-5EFF79D6-3FC9-4A6F-ADFB-5285A56793BA Q27676827-31D89E35-526A-4BF0-9E62-1295438076D3

P2860

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

http://www.wikidata.org/entity/Q24652600

description

2008 nî lūn-bûn

@nan

2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Discovery of a selective inhib ...... h potent antimelanoma activity

@ast

Discovery of a selective inhib ...... h potent antimelanoma activity

@en

Discovery of a selective inhib ...... h potent antimelanoma activity

@nl

type

label

Discovery of a selective inhib ...... h potent antimelanoma activity

@ast

Discovery of a selective inhib ...... h potent antimelanoma activity

@en

Discovery of a selective inhib ...... h potent antimelanoma activity

@nl

prefLabel

Discovery of a selective inhib ...... h potent antimelanoma activity

@ast

Discovery of a selective inhib ...... h potent antimelanoma activity

@en

Discovery of a selective inhib ...... h potent antimelanoma activity

@nl

P1433

Q24652600-D1AF42A5-CBE5-4DC4-8A99-8DEE40B5D223

P1476

Q24652600-C17F37B9-E820-4887-BA45-ABAAE91DB967

P2093

Q24652600-078A2588-D397-459A-BC2C-6C758595E5A7

Q24652600-084ECCBB-480E-4E88-947C-A0B0EE630FB0

Q24652600-091E1CC1-7C9B-448D-8FA6-4A12A7EE78B2

Q24652600-0EBAB73E-4B1E-41ED-B52E-6F38C7F2915B

Q24652600-1C64DAD5-1A0A-4AFF-B871-BC4A98A4730A

Q24652600-22143EF4-4FBF-41B4-A6F5-4B0FFE592B5F

Q24652600-2B82B71D-7BA8-4AF3-A7B4-4B2CB8DD2DA0

Q24652600-38851C3E-C1AC-44FC-B625-DA11EDD84F31

Q24652600-43462BC2-5770-479E-A2D2-E8A190C5CBA5

Q24652600-460D1876-3F9A-4609-BB7F-EB8578CA228D

P2860

Q24652600-05E41E84-0E11-490D-92E3-840057743B01

Q24652600-06BFFBEC-210B-4D0A-98B3-A1590DB9B433

Q24652600-11F1D3D8-F0CC-4B20-A388-1B559F8E7B16

Q24652600-15523D9C-62CC-453F-8B0D-B9DA96334338

Q24652600-16720E53-967B-4B38-BDD6-6920A2E30830

Q24652600-1B3C3133-638F-48CC-BBB0-CE921264625A

Q24652600-30F30BFC-DE1E-48F2-8788-F437AAB5EBAE

Q24652600-3D9EDE26-6008-4212-A9F2-6D617FA1A6BF

Q24652600-3EB30F29-4CB8-415C-ADF8-87DA4F84B5CE

Q24652600-437D0A7A-49C6-4852-8620-55DB66DA62B3

P304

Q24652600-495387A4-B134-401D-8C68-12532A2D6311

P31

Q24652600-09A3D12B-2CF5-417C-BABA-E0E58878F8CE

P3181

Q24652600-367104E1-9583-4EA9-9E7C-EE1FA11F30E9

P356

Q24652600-D19FF8A7-343E-4A04-8C39-DAF3C7CB904F

P407

Q24652600-A7CDBF94-611A-43ED-A860-7B1ADC5D96F9

P433

Q24652600-8F7E5F28-15B4-445F-89B5-A43B22D8A0CF

P478

Q24652600-37A7F5D0-BD11-43B0-A4C2-90B61309E3E5

P50

Q24652600-27AD370B-0880-4F99-84AB-0F2734481385

Q24652600-373AF0B1-541A-477D-8871-A2B2D0B125D2

Q24652600-47543C7A-437A-40C9-9ABF-EFBD3ACE30C1

Q24652600-6F7D93A8-A549-4E5B-B642-F6ED4DFD4A9B

Q24652600-918ADABD-0417-4747-A4CD-63F25E282B75

Q24652600-93A5848E-B96E-4875-B5ED-500D0A0C3EF0

Q24652600-A216A1FF-EB95-4162-A389-398524755468

Q24652600-CF679223-408D-4968-99DC-9EBD35718782

Q24652600-D0306244-FD6F-4F84-8C66-540076E45D35

P577

Q24652600-63146D4A-ADB0-454B-BA79-A3755D0B0CF3

P5875

Q24652600-1328070B-ADAA-436C-9476-68C011D6277F

P698

Q24652600-9F3BF7E3-2521-45E2-8703-534A1F420E25

P932

Q24652600-99C2E810-EB1A-488E-995D-C72C0299A60E

P3181

P356

PNAS.0711741105

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Discovery of a selective inhib ...... h potent antimelanoma activity

@en

P2093

Adhirai Marimuthu

http://www.w3.org/2001/XMLSchema#string

Ben Powell

http://www.w3.org/2001/XMLSchema#string

Billy Lam

http://www.w3.org/2001/XMLSchema#string

Brian L West

http://www.w3.org/2001/XMLSchema#string

Calvin Settachatgul

http://www.w3.org/2001/XMLSchema#string

Catherine Luu

http://www.w3.org/2001/XMLSchema#string

Daniel Fong

http://www.w3.org/2001/XMLSchema#string

Dean R Artis

http://www.w3.org/2001/XMLSchema#string

Hanna Cho

http://www.w3.org/2001/XMLSchema#string

Hoa Nguyen

http://www.w3.org/2001/XMLSchema#string

P2860

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

Mutations of the BRAF gene in human cancer

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

The discovery of potent cRaf1 kinase inhibitors

BRAF mutation predicts sensitivity to MEK inhibition

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

BRAFE600-associated senescence-like cell cycle arrest of human naevi

A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.

Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead.

P304

3041-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2469377

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.0711741105

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P50

Meenhard Herlyn

Joseph Schlessinger

Nikolas K. Haass

Keiran S M Smalley

P577

2008-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5565106

http://www.w3.org/2001/XMLSchema#string

P698

18287029

http://www.w3.org/2001/XMLSchema#string

P932

2268581

http://www.w3.org/2001/XMLSchema#string